Patents by Inventor Dagmar Prasa

Dagmar Prasa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substrates for TAFI (A)
    Patent number: 7718406
    Abstract: The invention relates to compounds of general formula (I) and acid addition salts thereof, where the various symbols have the meanings given in the description and claims, the production and use thereof as substrate for the detection of TAFIa, a fibrinolysis inhibiting enzyme. The detection occurs by using the absorption between 400 and 412 nm, arising as a result of the formation of 3-carboxy-4-nitrothiophenol from Ellman's reagent as a function of time.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: May 18, 2010
    Assignee: DSM IP Assets B.V.
    Inventors: Hugo Ziegler, Dagmar Prasa, Jörg Stürzebecher, Peter Wikstroem
  • Substrates for tafi (a)
    Publication number: 20060068457
    Abstract: The invention relates to compounds of general formula (I) and acid addition salts thereof, where the various symbols have the meanings given in the description and claims, the production and use thereof as substrate for the detection of TAFIa, a fibrinolysis inhibiting enzyme. The detection occurs by using the absorption between 400 and 412 nm, arising as a result of the formation of 3-carboxy-4-nitrothiophenol from Ellman's reagent as a function of time.
    Type: Application
    Filed: December 6, 2002
    Publication date: March 30, 2006
    Inventors: Hugo Ziegler, Dagmar Prasa, Jorg Sturzebecher, Peter Wilkstroem
  • Method for measuring the activity of the blood clotting factor XIIIA
    Publication number: 20030190692
    Abstract: The invention relates to a method for measuring the activity of the blood clotting factor XIIIa. The aim of the invention is to provide a method for measuring the activity of FXIIIa which is simple to carry out and which is also suitable for use with testing systems that have a high throughput. It was found that activated FXIIIa influences the light transmitting power of fibrin clots. Fibrinogen is caused to clot with a fibrinogen-splitting enzyme. The change in the light transmitting power of the samples according to the concentration of FXIIIa present is registered and is used as a measure of the activity of FXIIIa. The inventive method can be used especially for screening for FXIIIa inhibitors.
    Type: Application
    Filed: March 13, 2003
    Publication date: October 9, 2003
    Inventors: Dagmar Prasa, Jorg Sturzebecher